NASDAQ:ISEE IVERIC bio Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IVERIC bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.33 +0.41 (+8.33 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$4.87Now: $5.33▼$5.3850-Day Range$4.25MA: $4.85▼$6.2952-Week Range$0.91Now: $5.33▼$8.97Volume771,814 shsAverage Volume779,327 shsMarket Capitalization$477.05 millionP/E RatioN/ADividend YieldN/ABeta1.88 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingIVERIC bio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, IVERIC bio has a forecasted upside of 143.9% from its current price of $5.33.Amount of Analyst CoverageIVERIC bio has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesIVERIC bio has received 32 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIVERIC bio has received 41 “underperform” votes. (Add your “underperform” vote.)Community SentimentIVERIC bio has received 56.16% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IVERIC bio and other stocks. Vote “Outperform” if you believe ISEE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ISEE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of IVERIC bio is held by insiders.Percentage Held by Institutions85.67% of the stock of IVERIC bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to grow in the coming year, from ($1.12) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISEE Previous Symbol CUSIPN/A CIKN/A Webivericbio.com Phone212-845-8200Debt Debt-to-Equity RatioN/A Current Ratio21.13 Quick Ratio21.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$209.98 million Price / Sales2.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.82 per share Price / Book1.89Profitability EPS (Most Recent Fiscal Year)($1.39) Net Income$-58,860,000.00 Net MarginsN/A Return on Equity-47.75% Return on Assets-44.11%Miscellaneous Employees35 Outstanding Shares89,502,000Market Cap$477.05 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.33 +0.41 (+8.33 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ISEE News and Ratings via Email Sign-up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter. IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions How has IVERIC bio's stock price been impacted by Coronavirus? IVERIC bio's stock was trading at $4.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ISEE stock has increased by 19.5% and is now trading at $5.33. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of IVERIC bio? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IVERIC bio. When is IVERIC bio's next earnings date? IVERIC bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for IVERIC bio. How were IVERIC bio's earnings last quarter? IVERIC bio Inc (NASDAQ:ISEE) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.01. View IVERIC bio's earnings history. What price target have analysts set for ISEE? 3 equities research analysts have issued 12-month price objectives for IVERIC bio's stock. Their forecasts range from $13.00 to $13.00. On average, they expect IVERIC bio's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price. View analysts' price targets for IVERIC bio. Who are some of IVERIC bio's key competitors? Some companies that are related to IVERIC bio include Myovant Sciences (MYOV), Akcea Therapeutics (AKCA), CryoPort (CYRX), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Eidos Therapeutics (EIDX), Prestige Consumer Healthcare (PBH), Revance Therapeutics (RVNC), Kura Oncology (KURA), Uniqure (QURE), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD) and Y-mAbs Therapeutics (YMAB). View all competitors. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Tesla (TSLA), Exxon Mobil (XOM), Canopy Growth (CGC), Cisco Systems (CSCO), Gilead Sciences (GILD) and Intel (INTC). Who are IVERIC bio's key executives? IVERIC bio's management team includes the following people: Dr. David R. Guyer, Exec. Chairman (Age 59)Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44) What is IVERIC bio's stock symbol? IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE." Who are IVERIC bio's major shareholders? IVERIC bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RTW Investments LP (12.85%), Deerfield Management Company L.P. Series C (11.23%), Perceptive Advisors LLC (3.89%), Orbimed Advisors LLC (6.33%), Versant Venture Management LLC (3.36%) and Logos Global Management LP (1.75%). Company insiders that own IVERIC bio stock include David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View institutional ownership trends for IVERIC bio. Which institutional investors are selling IVERIC bio stock? ISEE stock was sold by a variety of institutional investors in the last quarter, including PDT Partners LLC, Jane Street Group LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have sold IVERIC bio company stock in the last year include David R Guyer, and Keith Westby. View insider buying and selling activity for IVERIC bio. Which institutional investors are buying IVERIC bio stock? ISEE stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Deerfield Management Company L.P. Series C, Orbimed Advisors LLC, Perceptive Advisors LLC, Versant Venture Management LLC, Logos Global Management LP, Goldman Sachs Group Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for IVERIC bio. How do I buy shares of IVERIC bio? Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is IVERIC bio's stock price today? One share of ISEE stock can currently be purchased for approximately $5.33. How big of a company is IVERIC bio? IVERIC bio has a market capitalization of $477.05 million and generates $209.98 million in revenue each year. The company earns $-58,860,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. IVERIC bio employs 35 workers across the globe. What is IVERIC bio's official website? The official website for IVERIC bio is ivericbio.com. How can I contact IVERIC bio? IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
